Stock Scorecard
Stock Summary for Pliant Therapeutics Inc (PLRX) - $13.30 as of 12/20/2024 3:58:11 PM EST
Total Score
8 out of 30
Safety Score
37 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for PLRX
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PLRX
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PLRX
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for PLRX
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for PLRX (37 out of 100)
Stock Price Rating (Max of 10) | 5 |
Historical Stock Price Rating (Max of 10) | 7 |
Stock Price Trend (Max of 10) | 2 |
Book Value (Max of 10) | 4 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 5 |
Analyst Strong Buy Ratings (Max of 5) | 5 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 9 |
Price to Earnings (Max of 10) | 0 |
Latest News for for PLRX
Financial Details for PLRX
Company Overview |
|
---|---|
Ticker | PLRX |
Company Name | Pliant Therapeutics Inc |
Country | USA |
Description | Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and markets new therapies for the treatment of fibrosis and related diseases in the United States. The company is headquartered in South San Francisco, California. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 9/30/2024 |
Next Earnings Date | 2/25/2025 |
Stock Price History |
|
Last Day Price | 13.30 |
Price 4 Years Ago | 22.72 |
Last Day Price Updated | 12/20/2024 3:58:11 PM EST |
Last Day Volume | 1,874,293 |
Average Daily Volume | 551,816 |
52-Week High | 19.62 |
52-Week Low | 10.22 |
Last Price to 52 Week Low | 30.14% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 21.25 |
Sector PE | 40.44 |
5-Year Average PE | -6.07 |
Free Cash Flow Ratio | 2.00 |
Industry Free Cash Flow Ratio | 11.59 |
Sector Free Cash Flow Ratio | 27.17 |
Current Ratio Most Recent Quarter | 10.26 |
Total Cash Per Share | 6.65 |
Book Value Per Share Most Recent Quarter | 5.68 |
Price to Book Ratio | 2.33 |
Industry Price to Book Ratio | 5.00 |
Sector Price to Book Ratio | 20.63 |
Price to Sales Ratio Twelve Trailing Months | 3,050.34 |
Industry Price to Sales Ratio Twelve Trailing Months | 81.68 |
Sector Price to Sales Ratio Twelve Trailing Months | 24.53 |
Analyst Buy Ratings | 8 |
Analyst Strong Buy Ratings | 5 |
Share Statistics |
|
Total Shares Outstanding | 60,854,000 |
Market Capitalization | 809,358,200 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -30.83% |
Reported EPS 12 Trailing Months | -3.35 |
Reported EPS Past Year | -2.65 |
Reported EPS Prior Year | -2.76 |
Net Income Twelve Trailing Months | -201,681,000 |
Net Income Past Year | -161,336,000 |
Net Income Prior Year | -123,321,000 |
Quarterly Revenue Growth YOY | -100.00% |
5-Year Revenue Growth | -80.44% |
Operating Margin Twelve Trailing Months | 0.00 |
Balance Sheet |
|
Total Cash Most Recent Quarter | 404,513,000 |
Total Cash Past Year | 494,245,000 |
Total Cash Prior Year | 331,187,000 |
Net Cash Position Most Recent Quarter | 374,374,000 |
Net Cash Position Past Year | 484,191,000 |
Long Term Debt Past Year | 10,054,000 |
Long Term Debt Prior Year | 9,929,000 |
Total Debt Most Recent Quarter | 30,139,000 |
Equity to Debt Ratio Past Year | 0.98 |
Equity to Debt Ratio Most Recent Quarter | 0.92 |
Total Stockholder Equity Past Year | 473,576,000 |
Total Stockholder Equity Prior Year | 313,342,000 |
Total Stockholder Equity Most Recent Quarter | 345,822,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -136,643,000 |
Free Cash Flow Per Share Twelve Trailing Months | -2.25 |
Free Cash Flow Past Year | -117,282,000 |
Free Cash Flow Prior Year | -96,391,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.06 |
MACD Signal | 0.10 |
20-Day Bollinger Lower Band | 11.05 |
20-Day Bollinger Middle Band | 13.22 |
20-Day Bollinger Upper Band | 15.40 |
Beta | 1.09 |
RSI | 49.61 |
50-Day SMA | 13.91 |
150-Day SMA | 16.59 |
200-Day SMA | 18.33 |
System |
|
Modified | 12/21/2024 9:30:17 AM EST |